Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Autologous Faecal Microbiota Transplantation to Improve Outcomes of Haematopoietic Stem Cell Transplantation: Results of a Single-Centre Feasibility Study

Anna Li
ORCID logo ,
Joanne Marie Bowen
,
Imogen A Ball
,
Sophie Wilson
,
Angelina Yong
,
David T Yeung
,
Cindy H Lee
,
Robert Venning V Bryant
,
Samuel P Costello
,
Feargal J. Ryan
,
Hannah R. Wardill
* ORCID logo
Version 1 : Received: 10 November 2023 / Approved: 10 November 2023 / Online: 10 November 2023 (11:56:32 CET)

A peer-reviewed article of this Preprint also exists.

Li, A.; Bowen, J.M.; Ball, I.A.; Wilson, S.; Yong, A.; Yeung, D.T.; Lee, C.H.; Bryant, R.V.; Costello, S.P.; Ryan, F.J.; Wardill, H.R. Autologous Faecal Microbiota Transplantation to Improve Outcomes of Haematopoietic Stem Cell Transplantation: Results of a Single-Centre Feasibility Study. Biomedicines 2023, 11, 3274. Li, A.; Bowen, J.M.; Ball, I.A.; Wilson, S.; Yong, A.; Yeung, D.T.; Lee, C.H.; Bryant, R.V.; Costello, S.P.; Ryan, F.J.; Wardill, H.R. Autologous Faecal Microbiota Transplantation to Improve Outcomes of Haematopoietic Stem Cell Transplantation: Results of a Single-Centre Feasibility Study. Biomedicines 2023, 11, 3274.

Abstract

Haematopoietic stem cell transplantation (HSCT) is a curative approach for blood cancers, yet its efficacy is undermined by a range of acute and chronic complications. In light of mounting evidence to suggest that these complications are linked to a dysbiotic gut microbiome, we aimed to evaluate the feasibility of faecal microbiota transplantation (FMT) delivered during the acute phase after HSCT. Of note, this trial opted for FMT prepared using the individual’s own stool (autologous FMT) to mitigate risks of disease transmission from donor stool. Adults (>18 years) with multiple myeloma were recruited from a single centre. Stool was collected prior to starting first-line therapy. Patients that progressed to HSCT were offered FMT via 3 x re-tention enemas before day +5 (HSCT = day 0). Feasibility was determined by recruitment rate, number and volume of enemas administered, and retention time. Longitudinally collected stool samples were also col-lected to explore the influence of auto-FMT using 16S rRNA gene sequencing. N=4 (2F:2M) participants received auto-FMT in 12 months. Participants received an average of 2.25(1-3) enemas (43.67(25-50)mL total, retained for an average of 60.78(10-145)minutes). No AEs, attributed to the FMT, were identified. Although minimum requirements were met for the volume and retention of auto-FMT, recruitment was significantly impacted by the logistical challenges of pre-therapy stool collection. This ultimately under-mined the feasibility of this trial and suggests that third party (donor) FMT should be prioritised.

Keywords

faecal microbiota transplantation; autologous faecal microbiota transplantation; autologous haematopoietic stem cell transplantation; haematopoietic stem cell transplantation; HSCT; bone marrow transplantation, multiple myeloma, gut microbiome, gut microbiota; supportive care, supportive oncology

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.